Heron Therapeutics (HRTX)

Executive Summary

Heron Therapeutics is a commercial-stage biopharmaceutical company focused on developing non-opioid pain management and antiemetic therapies using its proprietary Biochronomer® sustained-release platform. The company's approved products include ZYNRELEF (bupivacaine/meloxicam) for postoperative pain and SUSTOL (granisetron extended-release) for chemotherapy-induced nausea and vomiting (CINV). ZYNRELEF, the first and only dual-acting local anesthetic delivering bupivacaine and meloxicam, offers a significant alternative to opioids, while SUSTOL provides a convenient, sustained-release option for CINV prevention. As of 2026, Heron is focused on expanding commercial adoption and advancing its pipeline, which includes Phase 3 and earlier-stage candidates in analgesia and CINV. With a market capitalization of ~$229 million, the company faces competition but remains uniquely positioned in the non-opioid space, driving potential for revenue growth and eventual profitability.

Upcoming Catalysts (preview)

• Q3 2026Q2 2026 Earnings Report and Commercial Update80% success
• Q3 2026Potential FDA sNDA Acceptance for ZYNRELEF Expanded Indication50% success
• TBDInitiation of New Phase 3 Trial for APF530 in CINV60% success